Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTTP | P55157 | 12/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.34 |
| ▸ | KLRK1 | P26718 | 2/20 | 0.34 |
| ▸ | MICA | Q29983 | 2/20 | 0.34 |
| ▸ | RAET1L | Q5VY80 | 2/20 | 0.34 |
| ▸ | IGF2BP2 | Q9Y6M1 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065148 | 0.94 | MTTP (0.44) | MTTPKLRK1MICARAET1L | |
| SCHEMBL5068092 | 0.92 | MTTP (0.34) | MTTPNTRK1 | |
| SCHEMBL5062419 | 0.89 | MTTP (0.36) | MTTPKLRK1MICARAET1L | |
| SCHEMBL5062030 | 0.88 | MTTP (0.43) | MTTPKLRK1MICARAET1L | |
| SCHEMBL5065162 | 0.87 | NTRK1 (0.42) | MTTPRXFP1IGF2BP2NTRK1 | |
| SCHEMBL3722420 | 0.87 | MTTP (0.39) | MTTPRXFP1KLRK1MICARAET1L | |
| SCHEMBL5065207 | 0.87 | NTRK1 (0.35) | MTTPRXFP1IGF2BP2NTRK1 | |
| SCHEMBL5068184 | 0.86 | MTTP (0.44) | MTTP | |
| SCHEMBL14031684 | 0.86 | MTTP (0.43) | MTTPKLRK1MICARAET1L | |
| SCHEMBL5061989 | 0.86 | MTTP (0.45) | MTTPKLRK1MICARAET1L |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | claimed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-7432392-B2 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2008-10-07 | — | — | US | disclosed |
| US-20060205726-A1 | Ester derivatives and medical use thereof | JAPAN TOBACCO INC. (JP) | 2006-09-14 | — | — | US | disclosed |
| EP-1669345-A1 | ESTER DERIVATIVE AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205726-A1 | Ester derivatives and medical use thereof | MTTP, LIPC, CETP | MTTP 1/4885RXFP1 3022/4885KLRK1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.